R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

Trial Details

NCT ID
NCT06398418
Phase
PHASE1
Sponsor
Rise Therapeutics LLC
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • R-5780
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • At least 18 years of age to 80
  • Ability to provide written informed consent
  • Unresectable stage III or stage IV melanoma, basal cell carcinoma, or squamous cell carcinoma as per the American Joint Committee on Cancer 2017 Gu…
  • Refractory to anti-PD (checkpoint Protein on Immune Cells called T cells)-1/L1 therapy per RECIST v1.1 defined as subject who has disease progressi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →